Get started by downloading the provider guide or explore ordering options to bring MyRisk to your practice.
Download provider guide
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on MyRisk and your testing options.
Download patient guide
The MyRisk Hereditary Cancer Test helps you get the clarity you need to determine the best surgical and treatment options for your patient in 14 days or less. The multi-gene panel analyzes risk for 11 cancers to determine if your patient has a germline genetic mutation associated with an increased cancer risk.
Somatic testing alone can have some limitations including unknown variants, limited tumor tissue, and missed large rearrangements. Germline testing gives you the clarity you need to guide treatment decisions, including targeted therapies and surgical techniques.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend germline testing in the workup for patients diagnosed with, or after confirmation of, ovarian, breast, pancreatic, prostate, and colon cancer.1
A MyRisk germline test can provide comprehensive insights to help you and your patient reduce the occurrence of a subsequent primary cancer.
MyRisk germline testing is appropriate for patients diagnosed with:
*eligible for MyRisk STAT
MyRisk germline testing assesses more than 48 genes linked to one or more of 11 cancer sites. The results will list specific mutations found, including variants of uncertain significance (VUS). A summary of medical society guidelines to guide and optimize treatment decisions will also be provided in the MyRisk Management Tool (MMT).
A mutation has been identified.
An elevated risk has been identified.
No clinically significant mutation.
Mutation of uncertain risk has been identified.
Studies have shown that over 1/3 of conflicting variant classifications may alter patients’ medical management.2 Our tests have provided definitive classification for up to 63% of variants that other labs could not.3
Myriad offers RNA analysis to all patients with an eligible variant of unknown significance (VUS) after MyRisk testing is complete. Myriad will notify the healthcare provider when RNA analysis could help classify variants, giving providers and patients access to this valuable tool regardless of when, where, or how their MyRisk test was submitted.
There should not be a trade-off between turnaround time and receiving an accurate, comprehensive risk assessment when determining surgical treatment for patients. MyRisk STAT was developed for trusted results without the wait.
In addition to the 10 STAT genes, all MyRisk STAT orders will receive the full Myriad MyRisk Hereditary Cancer Panel report in 14 days or less.
Provider completes the test request form (in the portal or via paper TRF)
Patient blood or saliva sample is collected and submitted to Myriad Genetics with the test kit
Results are sent to the ordering provider (in the portal or via mail)
With Precise™ Oncology Solutions, you can receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including MyRisk, in one single ordering experience, getting clear, fast answers for your patients.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.
Every MyRisk test provides actionable results within two weeks to inform more confident patient treatment and surgical decisions.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
NCCN = National Comprehensive Cancer Network® (NCCN®)
†Patients with government payers (Medicare, Medicare Advantage, TriCare) are not eligible for MyRisk STAT.